12:00 AM
Nov 05, 2001
 |  BioCentury  |  Tools & Techniques

Oncolytic competition

One of the reasons companies want to move rapidly through the clinic is that competitors often are chasing them with improved second generation products. Whether this is the case with Onyx Pharmaceuticals Inc.'s ONYX-015 oncolytic adenovirus versus Schering-Plough Corp.'s new strain of oncolytic adenovirus, 01/PEME, only time and clinical testing will tell.

Researchers at SGP's Canji Inc. subsidiary (San Diego, Calif.) last week outlined in Nature Biotechnology the creation of 01/PEME and their comparison of it with ONYX-015.

In three different human tumor xenografts in mice, 01/PEME showed 70%, 43% and 64% better tumor inhibition than ONYX-015 (p= 0.0275, 0.0010, and 0.003,...

Read the full 504 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >